Safety comparison of two clot-busting drugs for acute stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This study compares the safety of two FDA-approved clot-dissolving medicines (rhTNK-tPA and rt-PA) given through an IV to patients having an acute ischemic stroke (a stroke caused by a blood clot in the brain). Researchers want to understand which treatment is safer and how well each works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your stroke symptoms started less than 4.5 hours ago
- Brain imaging (CT or MRI) confirms you had an ischemic stroke
- Your stroke severity score (NIHSS) is 25 or lower at admission
- You are scheduled to receive one of these two clot-busting medications by IV
- You can complete follow-up visits and cooperate with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two clot-dissolving medications (tenecteplase and reteplase) given before a procedure to remove a large clot from a brain artery. It aims to see which drug works better for people who have had an acute ischemic stroke and are eligible for both treatments.
This trial tests a clot-dissolving medication called rhTNK-tPA for people who had a stroke 4.5 to 24 hours ago. It aims to help those with certain types of blockages in the brain who are still having moderate to severe symptoms.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.
This trial compares two clot-busting medicines, TNK and TPA, given through an IV in a special ambulance (Mobile Stroke Unit) to treat acute ischemic stroke. The goal is to see which drug works better when started quickly after symptoms begin.
This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.